ClinicalTrials.gg
RecruitingNCT06959121NANOCLAMP-AFUpdated Sep 9, 2026

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

An interventional study of CellFX® nsPFA™ Cardiac Surgery System in Atrial Fibrillation, Maze Procedure and AF, sponsored by Pulse Biosciences, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Pulse Biosciences, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
328th of 679
135 · median 127
Started
2025
with 40 others
No phase
405 of 993
67 open now
Primary completion
2027-04
later than 99 of 219 live
Registered
929th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 328th largest by planned enrollment of the 679 interventional ones that give a count, is one of 41 that started in 2025, is one of 405 with no phase, reaches primary completion later than 99 of the 219 other live ones, and was the 929th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.

Read the detailed description

The study design is a prospective, multicenter, non-randomized single arm study. Eligible adult subjects with paroxysmal or persistent/longstanding persistent AF who are eligible to participate will undergo a concomitant cardiac surgical procedure with CellFX nsPFA Cardiac Surgery System ablation and left atrial appendage exclusion or removal. The left atrial wall isolation will include left and right pulmonary vein isolation as well as isolation of the left atrial posterior wall through left atrial roof and floor lesions. The left atrial posterior wall isolation (PWI) can be formed by either allowing a closed LA epicardial only lesion encompassing the entire posterior wall of the left atrium or by a combined epicardial/endocardial approach when the left atrium is open.

Primary effectiveness endpoint is freedom from any AF/AFL/AT lasting > 30 seconds and freedom for use of new or increased dose of previously failed Class I or III antiarrhythmic drugs (AADs) prescribed to treat atrial arrhythmias following the 90-day blanking period through 6 months post the concomitant surgical and ablation procedure by a core lab.

Primary safety endpoint is the incidence of acute major adverse events (MAEs), which includes death, stroke, myocardial infarction (MI), transient ischemic attack (TIA), or excessive bleeding (Bleeding Academic Research Consortium (BARC) 3b, 4, or 5) within 30 days post-concomitant surgical procedure. These events may be related to either the cardiac surgical procedure or the ablation procedure. All MAE events will be reviewed and adjudicated by an independent Clinical Events Committee (CEC).

03

Conditions studied

  • Atrial Fibrillation
  • Maze Procedure
  • AF
  • Ablation

Browse trials for

Keywords

  • nsPFA
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be between 18 and 85 years of age
  • Subject is willing and capable of providing to undergo study procedures which include the potential for surgical AF ablation, and completion of follow-up visits as specified in the clinical study protocol
  • Subject has history of documented paroxysmal atrial fibrillation (AF that is intermittent and terminates within ≤ 7 days of onset) or persistent/longstanding persistent atrial fibrillation (AF that is continuous and sustains for > 7 days and requires intervention) within one year prior to enrollment. Documentation may include , transtelephonic monitor (TTM), Holter monitor or telemetry strip from the study hospital or an outside physician
  • Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery via sternotomy for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, Atrial Septal Defect (ASD)/Patent Foramen Ovale (PFO) or Coronary artery bypass procedures
  • ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
  • Subject has a of at least 5 years
  • Subject currently lives within a reasonable commuting distance of the site and plans to remain geographically stable through 12 month follow up

Exclusion criteria

Exclusion Criteria:

  • Subject has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter-defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) or left atrial appendage (LAA) device
  • Subject has history or known to have LAA clot
  • Subject has a prosthetic heart valve
  • Stand- alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery
  • Prior cardiac surgery including prior cardiac surgical ablation
  • Left Atrial diameter ≥ 6cm
  • Wolff-Parkinson-White syndrome or other Supra-Ventricular Arrhythmia, Atrioventricular (AV) nodal reentry
  • Documented history of persistent or long standing persistent atrial fibrillation longer than 10 years
  • Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair/PFO and ascending aorta
  • Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation)
  • Subjects that are on an AAD for ventricular arrhythmia.
  • STS Predicted Risk of Mortality (STS PROM) of 10 or higher
  • Class III or IV (NYHA) heart failure symptoms
  • Prior history of stroke within 6 months
  • Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
  • Need for emergent cardiac surgery (per sit-to-stand (STS) test definition)
  • Known carotid artery stenosis greater than 80%
  • Current diagnosis of active systemic infection
  • Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
  • Renal failure requiring dialysis or hepatic failure (significant liver dysfunction with markedly significant elevation of liver enzymes, such as cirrhosis with decompensation, portal hypertension, or a history of hepatic failure)
  • A known drug and/or alcohol addiction
  • Mental impairment or other conditions that may not allow the subject to understand the nature, significance, and scope of the study
  • Pregnancy or desire to get pregnant within 12 months of the study treatment
  • Preoperative need for an intra-aortic balloon pump or intravenous inotropes
  • Subjects who have been treated with thoracic radiation
  • Subjects in current chemotherapy
  • Subjects on long-term treatment with oral or injected (not including intermittent use of inhaled steroids for respiratory diseases)
  • Subjects with known hypertrophic obstructive cardiomyopathy
  • Subjects with known cold agglutinin
  • Subject has a to anticoagulation (e.g., a bleeding or clotting disorder such as Idiopathic Thrombocytopenic Purpura (ITP))
  • Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  • > 45 kg/m2
  • Any diagnosed connective tissue disorder
  • Severe (COPD) per sit-to-stand (STS) test definition
  • Use of any other drug, therapy, or device within 30 days before enrollment or concurrent participation in another research study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    CellFX nsPFA Clamp

    Adult subjects who are eligible to participate will undergo a concomitant cardiac surgical procedure with nsPFA ablation (of left and right pulmonary veins as well as roof and floor lesions to form a box) and treatment of left atrial appendage.

    Device: CellFX® nsPFA™ Cardiac Surgery System

Interventions

  • DeviceCellFX® nsPFA™ Cardiac Surgery System

    Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp

06

What researchers measure

Primary outcomes

  1. Freedom from atrial fibrillation/atrial flutter/atrial tachycardia

    Freedom from AF/AFL/AT of 30 seconds or greater duration and freedom for use of new or increased dose of previously failed Class I or III antiarrhythmic drugs (AADs) prescribed to treat atrial arrhythmias.

    Time frame: 3-months through 6 months post-index procedure

  2. Incidence of Treatment-Emergent Adverse Events

    Rate of acute major adverse events (MAEs) which includes death, stroke, myocardial infarction (MI), and transient ischemic attack (TIA) or excessive bleeding (Bleeding Academic Research Consortium (BARC) 3b, 4 or 5).

    Time frame: Within 30 days post-concomitant surgical procedure

Secondary outcomes

  1. Acute electrical isolation of the pulmonary veins

    Acute electrical isolation of the left and right pulmonary veins and left atrial posterior wall by means of either intraoperative entrance or exit block testing

    Time frame: Immediately post-ablation procedure

  2. Freedom from atrial fibrillation/atrial flutter/atrial tachycardia

    Freedom from AF/AFL/AT of 30 seconds and freedom from use of new or increased dose of previously failed Class I or III AADs prescribed to treat atrial arrhythmias

    Time frame: Within 12 months post-ablation procedure

  3. Patient-Reported Outcome Measures (PROMs) for quality of life assessing well-being across physical, mental, and social domains

    Quality of Life (QoL) as measured using AFEQT and SF-12 (Physical Component Summary (PCS), Mental Component Summary (MCS) and General Health (GH))

    Time frame: 6 and 12 months post-ablation procedure

07

Study locations

3 of 3 sites recruiting
  • Adventist Heart Institute: Adventist Health St. Helena
    St. Helena, California 94574, United States
    Recruiting
    • Aaron M Kime, MD · Contact707-963-7200
  • Orlando Health
    Orlando, Florida 32806, United States
    Recruiting
  • Cardiac Surgery Clinic | Frankel Cardiovascular Center
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Matthew A Romano, MD · Contact888-287-1082
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 18 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Oct 23, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Dec 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06959121
Lead sponsor
Pulse Biosciences, Inc.
Collaborators
Avania
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Oct 23, 2025
Primary completion
Apr 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Shweta Kalpa, MD
Contact
Shweta.Kalpa@pulsebiosciences.com
(800) 543-3695
Matthew A. Romano, MD
principal investigator · University of Michigan, Cardiac Surgery Clinic | Frankel Cardiovascular Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion